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Hepatic arterial infusion chemotherapy
followed by sorafenib in patients with
advanced hepatocellular carcinoma (HICS
55): an open label, non-comparative, phase
II trial
Masahiro Hatooka1, Tomokazu Kawaoka1, Hiroshi Aikata1*, Yuki Inagaki1, Kei Morio1, Takashi Nakahara1,
Eisuke Murakami1, Masataka Tsuge1, Akira Hiramatsu1, Michio Imamura1, Yoshiiku Kawakami1, Kazuo Awai2,
Keiichi Masaki3, Koji Waki3, Hirotaka Kohno4, Hiroshi Kohno4, Takashi Moriya5, Yuko Nagaoki6, Toru Tamura6,
Hajime Amano7, Yoshio Katamura7 and Kazuaki Chayama1,8,9
Abstract
Background: In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic
arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative
phase II study to assess survival with HAIC or HAIC converted to sorafenib.
Methods: Fifty-five patients were prospectively enrolled. Patients received HAIC as a second course if they had complete
response, partial response, or stable disease (SD) with an alpha fetoprotein (AFP) ratio < 1 or a des-γ-carboxy prothrombin
(DCP) ratio < 1. Patients were switched to sorafenib if they had SD with an AFP ratio > 1 and a DCP ratio > 1 or disease
progression. The primary endpoint was the 1-year survival rate. Secondary endpoints were the 2-year survival rate, HAIC
response, survival rate among HAIC responders, progression-free survival, and adverse events.
Results: Of the 55 patients in the intent-to-treat population, the 1-year and 2-year survival rates were 64.0 and 48.3%,
respectively. After the first course of HAIC, one (1.8%) patient showed complete response, 13 (23.6%) showed partial
response, 30 (54.5%) had SD, and 10 (18.1%) patients had progressive disease. Twenty-three patients (41.8%) had SD
with AFP ratios < 1 or DCP ratios < 1, and 7 (12.7%) had SD with AFP ratios > 1 and DCP ratios > 1. Thirty-seven
patients (68.5%) were responders and 17 (30.9%) were non-responders to HAIC. In responders, the 1-year and 2-year
survival rates were 78 and 62%, respectively.
Conclusion: Given the results of this study, this protocol deserves consideration for patients with advanced HCC. This
trial was registered prospectively from December 12. 2012 to September 1. 2016.
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Background
Hepatocellular carcinoma (HCC) is the sixth most common
cancer and the second leading cause of cancer-related mor-
tality in the world. [1, 2]. Advances in technology have con-
tributed to development of new diagnostic techniques such
as ultrasonography, computed tomography, magnetic res-
onance imaging, and angiography. Similarly, new treatment
modalities have been developed, including surgical resec-
tion, radiofrequency ablation [3], percutaneous ethanol in-
jection, transcatheter arterial chemoembolization (TACE),
and hepatic arterial infusion chemotherapy (HAIC),
resulting in improved prognosis in HCC patients [4–12].
However, the survival rates are still poor for patients with
advanced HCC with associated complications such as por-
tal vein tumor thrombosis, and refractoriness to TACE.
Two phase III clinical trials of sorafenib for advanced
HCC showed significant efficacy in terms of overall sur-
vival (OS) time compared with placebo [13, 14]. Based
on these studies, sorafenib has become the standard of
therapy for advanced HCC. Sorafenib is associated with
extension of OS time by 2.3–2.8 months and the im-
provement of response rate by 2.0–3.3%. However, the
survival advantage of sorafenib has been described as
insufficient.
HAIC is widely used throughout Asia, especially in
Japan. Several studies have shown the survival benefits
of HAIC for advanced HCC free of extrahepatic metas-
tasis (extrahepatic spread, or EHS), with response rates
ranging from 20.8 to 52%, and have shown that the me-
dian survival time (MST) in responders ranges from
17.6–40.7 months [11, 12, 15–18]. In most retrospective
studies, the survival time was much better among re-
sponders than non-responders. Nevertheless, HAIC is not
regarded as the standard of care for advanced HCC pa-
tients as no prospective randomized phase III trials have
shown survival benefits in patients with advanced HCC.
Among responders, a better prognosis was expected
with HAIC compared with sorafenib, while HAIC
non-responders had a poor prognosis at 6 months in
previous studies. Therefore, it is necessary to identify
HAIC non-responders as early as possible.
In a previous study, we reported that patients showing
either complete or partial response (CR and PR respect-
ively) by the first course of HAIC had good prognoses,
whereas patients with progressive disease [19] by the
first course of HAIC had poor prognoses. However, we
observed that the majority of patients had stable disease
(SD) after the first course of HAIC. Furthermore, we
reported that among patients determined to have SD
based on the imaging response to the first course of HAIC,
those with alpha fetoprotein (AFP) and des-γ-carboxy pro-
thrombin (DCP) ratios > 1 had significantly poorer survival
times [20].That is, patients in whom AFP or DCP levels
decreased had better prognoses than those in whom AFP
or DCP levels increased. Therefore, we considered patients
to be HAIC responders in the first course of HAIC when
they showed CR, PR, or SD with decreased levels of AFP or
DCP. We defined HAIC non-responders as either patients
with PD or patients with SD who had increased levels of
AFP and DCP after the first course of HAIC.
Few prospective studies of HAIC have been performed.
No study protocols have been examined in which HAIC
was continued only in responders while non-responders
were switched to sorafenib where the outcome of the first
course of HAIC was determined by early assessment of
tumor markers and imaging responses. Therefore, we cre-
ated a protocol in which HAIC was continued unless the
outcome of therapy was non-response, and non-responders
were then switched from HAIC to sorafenib.
Methods
Study design
The phase II HICS study (Hepatic Arterial Infusion
Chemotherapy followed by Sorafenib) was a single-arm,
prospective, open-label trial. In this study, the primary
endpoint was the survival rate at 1 year. The secondary
endpoints were the survival rate at 2 years, overall sur-
vival (OS), response to HAIC, survival rate according to
HAIC response, progression-free survival (PFS), and ad-
verse events (AEs). The primary endpoint, survival rate
at 1 year, was defined as the probability of patients being
alive 1 year after their first course of HAIC. OS was de-
fined as the time from the start of the study treatment
to the death due to any reason. PFS was defined as the
time from the start of study treatment to the first docu-
mentation of objective tumor progression or to death
due to any cause.
One month after the first course of HAIC, therapeutic
efficacy was assessed by imaging studies and AFP/DCP.
Results of imaging studies were assessed according to
the Response Evaluation Criteria In Solid Tumors.
Safety assessments of the drugs included recording of
AEs, changes in laboratory test results, physical examin-
ation, and vital signs. Adverse events associated with the
drugs were those listed in the Common Terminology
Criteria for Adverse Events (CTCAE) 4.0.
The study was registered with the University Hospital
Medical Information Network Clinical Trials Registry as
HICS 55, with the identifier number UMIN 000009094.
The study was approved by the ethics committee and con-
ducted in accordance with the Declaration of Helsinki.
Informed consent was obtained from each patient.
Patients
Key inclusion criteria were as follows: minimum age of
20 years; life expectancy of at least 12 weeks at the pre--
treatment evaluation; advanced HCC based on histological
evidence via biopsy specimen or dynamic computed
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tomography or magnetic resonance imaging; not eligible
for resection or local ablation therapy or TACE; at least
4 weeks since the last therapy for HCC; no prior sorafenib
and HAIC treatment; no intrahepatic tumor that could
affect patient prognosis; Eastern Cooperative Oncology
Group performance status of 0 or 1; Child-Pugh score
of 5, 6, or 7; and adequate bone marrow, liver, and renal
function, as assessed by the following laboratory re-
quirements: granulocyte count ≥3000/mm3, platelet
count ≥50,000 /mm3, hemoglobin ≥8.5 g/dL, total serum
bilirubin ≤3 mg/dL, serum albumin ≥2.8, serum creatinine
≤1.5 mg/dL, prothrombin consumption test ≥50%, and
amylase ≤ twice the upper limit of normal. Key exclusion
criteria were as follows: other malignant disease, preg-
nancy or suspected pregnancy, severe infectious disease,
history of severe allergy, severe renal function disease, se-
vere allergy to 5-fluorouracil or cisplatin, severe bone mar-
row suppression, esophageal and/or gastric varices with a
high risk of bleeding and clinically significant gastrointes-
tinal bleeding, or serious hypertension. Patients who were
unstable or whose safety or compliance in the study could
be jeopardized based on the investigator’s judgment were
also excluded.
Treatments
Figure 1 illustrates the study schema. HAIC was adminis-
tered as the first therapy. Within one month after HAIC
administration, efficacy was assessed by imaging studies
and AFP/DCP. Patients who showed CR or PR or SD with
AFP ratio < 1 or DCP ratio < 1 were defined as responders.
Patients who showed SD with AFP ratio > 1 and DCP
ratio > 1 or PD [19] were defined as non-responders. Re-
sponders continued HAIC while non-responders were
switched from HAIC to sorafenib. The therapeutic efficacy
of sorafenib was assessed by imaging studies and AFP/
DCP one month after starting therapy. TACE was pro-
vided to partial and non-responders during this study.
Hepatic arterial infusion chemotherapy
Cisplatin was administered at a dose of 20 mg/m2/day
on days 1 and 8, and fluorouracil was administered at a
dose of 330 mg/m2/day on days 1–5 and 8–12 of every
28-day cycle, followed by 2 weeks off. HAIC was inter-
rupted in patients who experienced hematologic and
non-hematologic toxicities attributed to HAIC.
Sorafenib
Sorafenib 400 mg bid was used for the treatment of patients
who switched from HAIC. Sorafenib doses were adjusted,
by interruption or reduction, in patients who experienced
clinically significant hematologic or non-hematologic toxic-
ities attributed to sorafenib. Sorafenib doses were reduced
stepwise from 400 mg twice daily to 400 mg once daily to
400 mg every other day to 200 mg every other day as war-
ranted. Stepwise increases were allowed after resolution of
the AE. TACE, radiation therapy, and hepatectomy were
allowed as additional therapies.
Statistical analysis
We assumed a threshold survival rate at 1 year of 45% with
an expected survival rate at 1 year of 60% (0.1 α-error and
0.1 β-error). From these, we predicted that 46 patients
would qualify and established a patient enrollment target of
55 assuming that 20% would be disqualified.
Statistical analysis was performed using SPSS (IBM,
Armonk, NY, USA). Continuous variables are expressed
Evaluation in each course using RECIST 
and tumor marker ratio
CR/PR
HAIC 2nd course Conversion to sorafenib
HAIC 1st course 
HAIC responder HAIC non-responder
PD
SD with AFP > 1 and DCP > 1
Fig. 1 Study schema. Abbreviations: AFP alpha fetoprotein, CR complete response, DCP des-gamma-carboxy prothrombin, FP, HAIC hepatic arterial
infusion chemotherapy, PD progressive disease, PR partial response, SD stable disease
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as medians and ranges, while categorical variables are
expressed as counts or frequencies. Kaplan–Meier survival
curves with log-rank tests were used for the analysis of
OS. The statistical analysis was performed in September
2017. Differences between groups were examined for stat-
istical significance using the Mann-Whitney U test, logis-
tic regression test, or chi-square test as appropriate. The
cumulative survival rate was calculated from the date of
initiation of HAIC and assessed by the Kaplan-Meier
life-table method. Differences between groups were evalu-
ated by the log-rank test. For baseline characteristics such
as performance status, age, stage of disease, and history of
therapy, we calculated frequencies, averages, and medians
to assess their distribution.
Variables that achieved statistical significance (P < 0.05)
or marginal significance (P < 0.10) in the univariate ana-
lysis were entered into multiple logistic regression analysis
to identify significant independent predictive responders.
Multivariate Cox proportional hazards regression was
performed to assess the independent prognostic factors.
For both univariate and multivariate analyses, all inde-
pendent factors that demonstrated statistical significance
as a predictor were analyzed using stepwise selection in
the model. Hazard ratios and corresponding 95% confi-
dence intervals are reported.
Results
Baseline characteristics
Between December 2012 and October 2016, 55 patients
with unresectable HCC were enrolled in this study at par-
ticipating hospitals in the Hiroshima Liver study group.
The median period of observation was 12.2 months with a
range of 2.1 to 54.6 months. The data was last updated on
September 2017.
Patient characteristics are listed in Table 1. The major-
ity of study subjects were male, with a median age of
66 years. Among 29 patients who had Vp 3 and 4, 19 pa-
tients received three-dimensional conformal radiother-
apy. Patients received HAIC therapy a median of two
times (range: 0 to 11 times).
Efficacy
Figure 2 shows the flow of patients through the study.
The number of responders was 37 patients (68.5%), and
the number of non-responders was 17 patients (30.9%).
Among the responders, 32 patients received a second
course of HAIC. Five patients could not undergo the sec-
ond course because of angitis, catheter occlusion, or wors-
ening of performance status. Among the non-responders,
7 patients switched to sorafenib, whereas 10 patients were
ineligible for sorafenib treatment due to liver dysfunction,
disease progression, or worsening of performance status.
The imaging response by the Response Evaluation Criteria
In Solid Tumors to the first course of treatment was CR
in one (1.8%) patient, PR in 13 (23.6%), SD in 30 (54.5%),
and PD in 10 (18.1%) patients. SD patients were classified
into two groups: 23 patients (41.8%) had SD with AFP ra-
tio < 1 or DCP ratio < 1, whereas 7 (12.7%) had SD with
AFP ratio > 1 and DCP ratio > 1.
Survival
Among 55 patients, 27 patients died of HCC; no patients
died of other diseases.
In the intent-to-treat population, the 1-year and 2-year
survival rates were 64.0 and 48.3%, respectively (Fig. 3a).
The median survival time was 19.9 months, and the PFS
of the responders to HAIC was 5.0 months (Fig. 3b).
The MST of the responders to HAIC and of the
non-responders to the first course of HAIC were 30.5
and 7.7 months, respectively. MST differed significantly
between the responders and non-responders (P < 0.001). In
the responders, the 1-year and 2-year survival rates were 78
Table 1 Background characteristics of patients who received
hepatic arterial infusion chemotherapy
Characteristics Median (range) or
patient numbers
Age (years) 66 (32–88)
Gender (M/F) 49/6
ECOG performance status (0/1) 50/5
Etiology (HBV/HCV/others) 14/24/17
Platelet count (/mm3) 15.6 (6.4–41.4)
Total bilirubin (mg/dL) 0.9 (0.3–1.8)
Albumin (g/dL) 3.7 (2.7–5.0)
Prothrombin consumption test (%) 78 (57.4–118)
Child-Pugh score (5/6/7) 22/23/10
Number of liver tumors 5 (1–40)
Size of liver tumors (mm) 85 (18–170)
Macroscopic vascular invasion (without/with) 17/38
Vp (0–2/3–4)a 26/29
Vv (0–1/2–3) 46/9
Relative tumor size in the liver (< 50%/≥ 50%) 47/8
TACE refractory (without/with) 42/13
Extrahepatic spread (without/with) 49/6
HCC stage (III/IVa/IVb)b 30/22/3
BCLC stage (B/C)c 18/37
AFP (ng/mL) 1895.2 (2.6–529,500)
DCP (mAU/mL) 3854 (24–226,990)
Abbreviations: AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin,
ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCC
hepatocellular carcinoma, HCV hepatitis C virus, Vp portal invasion, Vv
venous invasion
aVp0 through Vp4 indicated no, third branch, second branch (segmental
invasion), first branch (branch invasion) and main portal vein invasion,
respectively, according to Liver Cancer Study Group of Japan criteria
bAccording to the Liver Cancer Group of Japan
cBCLC: Barcelona Clinic Liver Cancer,
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and 62%, respectively. In the non-responders, the 1-year and
2-year survival rates were 28 and 12%, respectively (Fig. 4a).
MST differed significantly among the imaging response
groups (P < 0.0001): 26.6, 30.5, 12.0, and 6.0 months in
patients with PR, SD (AFP ratio < 1 or DCP ratio < 1),
SD (AFP ratio > 1 and DCP ratio > 1), and PD, respect-
ively (Fig. 4b).
Safety profile
Adverse events (AE) during the first course of HAIC are
shown in Table 2. The most common AEs were anemia,
platelet count decrease, AST/ALT increase and leuco-
cyte count decrease. However, the frequency of AE ≥
grade 3 was 21.8%.
Predictive parameters of efficacy and overall survival
The univariate analysis identified three parameters that
were correlated either significantly or marginally with
response: TACE refractory status (without TACE re-
fractory; P = 0.007), and MVI (without MVI; P = 0.018).
TACE refractory status and MVI were entered into the
multiple logistic regression analysis to identify significant
Patients who were enrolled in 
HAIC (n=55)
HAIC responder
67.2% (n=37)
HAIC non-responder
30.9% (n=17)
Second course of HAIC
86.5% (n=32)
Conversion to sorafenib
41.1% (n=7) 
Dislocation of tip of catheter (n=1) 
Disease progression
(n=3)
Liver dysfunction
(n=4)
Angitis (n=3)   
catheter occlusion (n=1)
Worsening of performance 
status (n=1)
Worsening of 
performance 
status (n=3)
1st course of HAIC
Fig. 2 Patient flow chart. Abbreviations: HAIC hepatic arterial infusion chemotherapy
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independent predictive factors. The multivariate analysis
identified the without-TACE refractory stratus as the only
significant and independent factor that influenced re-
sponse (Table 3).
By means of univariate analysis, we then investigated
the relationship between survival after the initiation of
HAIC treatment and various clinicopathological vari-
ables (Table 4). Child-Pugh A, platelet count, DCP and
EHS correlated significantly with OS. The above parameters
were then entered into a multiple Cox proportional-hazard
model analysis. This analysis identified EHS as a significant
and independent determinant of survival.
Subgroup analysis was performed according to Child-Pugh
status, macroscopic vessel invasion, EHS and TACE
refractory status. MST (25 months) of Child-Pugh A
patients was significantly longer than that (13 months)
of Child-Pugh B patients (P = 0.0007) (Fig. 5a). The MST of
patients who had HCC with and without macroscopic ves-
sel invasion were not significantly different: 25.4 months
and 16.3 months, respectively (Fig. 5b). The MST of
P < 0.001
Follow-up period (months)
lavivrusll are v
O
Responder
Non-responder- - -
a
Number at risk
37    34    27      17    14     10       7      6       2      1       0
17    9      3        1      1       0 
Responder
Non-responder
P < 0.001
Follow-up period (months)
O
ve
ra
ll 
su
rv
iv
al
b
Number at risk
CR 1
PR 13 12    10      5        5       3      3       2      1      0
22    21    16     11       8       6      4       4      1      1      0
6      6      3       1        1       0
PD     9      3      0
DO     1      0
SD with 
AFP<1 or DCP<1
SD with
AFP>1 and DCP>1
CR
PR
SD with 
AFP<1 or DCP<1
SD with 
AFP>1 and DCP>1
PD
DO          
Fig. 4 (a) Overall survival according to response (b) Overall survival according to responder or non-responder status
Table 2 Adverse events associated with the first course of hepatic arterial infusion chemotherapy
No. (%) Grade 1 Grade 2 Grade 3 Grade 4 Total
Clinical
Nausea/Vomiting 9 (17) 2 (4) 0 0 11(20)
Anorexia 10 (19) 7 (13) 1(25) 0 18 (33)
Fever 5 (9) 1 (25) 0 0 6 (11)
Pain 11 (20) 0 0 0 11 (20)
Fatigue 8 (15) 1(25) 0 0 9 (17)
Diarrhea 0 1(25) 0 0 1(25)
Laboratory abnormalities
Leucocyte count decrease 22 (41) 6 (11) 1(25) 0 29 (54)
Neutrophil count decrease 10 (19) 2 (4) 0 0 12 (22)
Anemia 26 (48) 7 (13) 2 (4) 0 35 (65)
Platelet count decrease 22 (41) 9 (17) 4 (7) 0 35 (65)
AST/ALT increase 24 (44) 4 (7) 4 (7) 0 32 (59)
Creatinine increase 15 (28) 0 0 0 15 (28)
Total 12 (21.8) 0 (0)
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase
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patients who had HCC without EHS was significantly
longer than that of patients who had HCC with EHS
(26.6 vs 6.3 months, respectively) (P < 0.001) (Fig. 5c).
The MST of patients without and with TACE refractory
status was not significantly different: 25.4 months and
16.3 months, respectively (Fig. 5d).
Discussion
We investigated the efficacy of a protocol in which
HAIC was selected as the first-line therapy for patients
with advanced HCC and sorafenib was selected as the
second-line therapy for patients refractory to HAIC. In
our study, the 1-year and 2-year survival rates were 64.0
and 48.3%, and the MST was 19.9 months. OS was judged
to be favorable with HAIC as first-line therapy for patients
with advanced HCC. The rate of AEs (grade ≥ 3: 21.8%)
was judged to be acceptable by the investigators.
Sorafenib is currently the standard first-line therapy
for advanced HCC patients. However, the MST and re-
sponse rate were almost 10 months and 10% with sorafe-
nib therapy, respectively. In addition, HAIC is not used
as a standard therapy for advanced HCC patients due to
the lack of clinical trial data supporting its use.
The primary endpoint of the 1-year survival rate was
64.0%, and the MST was 30.5 months. When we compared
our protocol to other treatment protocols for advanced
HCC, the 1-year survival rates in the SHARP study and in
the Asia-Pacific study of sorafenib monotherapy were 44
and 32%, respectively [13, 14]. HAIC therapy followed by
sorafenib was superior to sorafenib monotherapy. In sub-
group analysis of our study, the MST of patients who had
Table 3 Univariate and multivariate analyses of factors associated with response
Parameters Univariate analysis Multivariate analysis
P value Odds ratio 95% CI P value
Age (< 65/≥ 65 years) 0.462
Gender (Male/Female) 0.917
ECOG performance status (0/1) 0.667
Platelet count (< 14.9 × 104/> 14.9 × 104 /μL) 0.487
Child-Pugh score (A/B) 0.736
Diameter of main tumor (< 80 mm/≥ 80 mm) 0.52
Macroscopic vascular invasion (without/with) 0.018
TACE refractory (without/with) 0.007 5.689 1.490–21.724 0.011
AFP (< 1895/≥ 1895 ng /mL) 0.149
DCP (< 3854/≥ 3854 mAU/mL) 0.547
Extrahepatic spread (without/with) 0.3
Abbreviations: AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin, ECOG Eastern Cooperative Oncology Group, MVI macroscopic vascular invasion, TACE
transarterial chemoembolization
Table 4 Univariate and multivariate analyses for determinants of overall survival
Parameters Univariate analysis Multivariate analysis
P value Hazard ratio 95% CI P value
Age (< 65/≥65 years) 0.304
Gender (Male/Female) 0.325
ECOG performance status (0/1) 0.187
Platelet count (< 14.9 × 104/> 14.9 × 104 /μL) 0.07
Child-Pugh score (A/B) 0.008
Diameter of main tumor(< 80 mm/≥ 80 mm) 0.036
Macroscopic vascular invasion (without/with) 0.646
TACE refractory (without/with) 0.101
AFP (< 1895/≥ 1895 ng /mL) 0.515
DCP (< 3854/≥ 3854 mAU/mL) 0.055
Extrahepatic spread (without/with) 0.004 3.905 1.420–10.736 0.008
Abbreviations: AFP alpha-fetoprotein, DCP des-gamma-carboxy prothrombin, ECOG Eastern Cooperative Oncology Group, MVI macroscopic vascular invasion, TACE
transarterial chemoembolization
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HCC with and without macroscopic vessel invasion was
not significantly different: 25.4 months and 16.3 months,
respectively (Fig. 5b). The MST of patients who had HCC
without EHS was significantly longer than that of patients
who had HCC with EHS (26.6 vs 6.3 months, respectively)
(P < 0.001) (Fig. 5c). Bruix et al. reported that the MST of
patients who had HCC with and without macroscopic ves-
sel invasion were 8.1 months and 14.1 months, respectively,
in sub-analysis of the SHARP study [21]. Cheng et al.
reported that the MST of patients who had HCC with
macroscopic vessel invasion and/or EHS was 5.6 months,
and the MST of patients who had HCC without macro-
scopic vessel invasion or EHS was 14.3 months, respect-
ively, in sub-analysis of the Asia-Pacific trial. Therefore,
HAIC therapy followed by sorafenib was superior to so-
rafenib monotherapy in patients with macroscopic ves-
sel invasion. HAIC therapy followed by sorafenib was
not inferior to sorafenib monotherapy in patients with
EHS [21]. Furthermore, we compared our protocol to a
previous HAIC study. Nouso et al. reported that the
1-year survival rate of HAIC was 52% in a nationwide
study in Japan [22]. Although, there were few differences
between our protocol and Nouso’s study, results of HAIC
therapy followed by sorafenib in our study was super-
ior to that of the previous HAIC study. The reason for
our favorable results could be that we continued HAIC
in HAIC responders, who are expected to have good
prognoses, and switched to sorafenib therapy in HAIC
non-responders, avoiding unnecessary AEs associated
with HAIC.
In our study, 21.8% of patients had AE ≥ grade 3.
Similar to our study, rates of AE ≥ grade 3 were 36 and
23.5% in the SHARP and Asia-Pacific studies, respect-
ively [13, 14]. While occlusion of catheter and angitis as
HAIC-specific AEs were observed in our study, the
rates of HAIC-specific AEs in this study were similar to
those of previous studies [11, 12].
Our multivariate analysis identified TACE non-refractory
status as the only significant and independent factor
that influenced response. In addition, a multiple Cox
proportional-hazard model analysis identified lack of
EHS as a significant and independent determinant for
OS. Retrospective studies have shown similar results. In
two studies, OS was significantly longer in those treated
with sorafenib compared with HAIC in HCC patients
refractory to TACE. A possible reason is that those studies
involved shorter duration of HAIC and a need to withdraw
the treatment due to stenosis of hepatic artery by catheter
therapy, reduced sensitivity to the drug, deterioration of
liver function, and appearance of collateral arteries [23, 24].
Another study reported that EHS was a poor prognosis fac-
tor in HAIC therapy [25]. Given these results, if our study
protocol were to be conducted in patients with TACE
non-refractory status and without EHS, favorable results
are likely. This protocol should therefore be taken into con-
sideration in the study design of a future clinical trial.
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Fig. 5 (a) Overall survival according to Child Pugh grade (b), macroscopic vessel invasion (MVI), (c) extrahepatic spread (EHS), and (d) transcatheter
arterial chemoembolization (TACE) refractory
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The study had several limitations: it was a single-arm
study with a small sample size and a narrow period of
observation. While we need to follow the prognosis over
a longer time period, the results of this prospective study
show the usefulness of this protocol as a first-line ther-
apy for patients with advanced HCC. Larger comparative
studies are necessary to confirm this conclusion.
Conclusion
We found favorable outcomes in patients with advanced
HCC treated with HAIC as first-line therapy. Given the
results of this study, this protocol deserves consideration
as an optional therapy for advanced HCC patients in the
future.
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